Executive Summary

California Governor Gavin Newsom's latest budget proposal would permanently cap the business tax credits companies can claim each year, aimed largely at the state's R&D tax credit. The cap would take effect in tax year 2027, limiting annual credit usage to $5 million or 50% of a company's tax liability, whichever is greater. While the change targets California's largest corporate taxpayers, it sends a clear signal to every R&D-intensive business: State innovation incentives are not static, and the cost of leaving credits unclaimed (or unmanaged) keeps rising.

What is California proposing?

Under the proposal in the Governor's May budget revision, businesses would face a permanent annual cap on the tax credits they can apply against their California tax bill, set at $5 million or 50% of tax liability, whichever is greater. The cap would not apply to net operating losses, and the credits themselves wouldn't disappear. Rather, companies simply couldn't use them as quickly.

If that sounds familiar, it's because California already imposed a temporary $5 million business credit limitation for tax years 2024 through 2026, also driven by budget pressures. The new proposal would make that kind of restriction permanent starting in 2027.

The state's Legislative Analyst's Office estimates California currently forgoes roughly $3.5 billion per year through R&D tax credits, and projects the cap would raise $850 million in 2026-27 and $1.7 to $1.8 billion annually through the end of the decade. According to the LAO, the cap would directly affect fewer than 100 of the state's largest corporate taxpayers.

Why are life sciences and tech companies concerned?

California's life sciences sector (which employs more than 336,000 people directly and contributes nearly $400 billion in annual economic impact) has been the most vocal opponent. Industry groups like California Life Sciences and Biocom argue the cap arrives at the worst possible time, as federal research funding through the NIH faces cuts and competition from international biotech hubs intensifies.

Their core concern: Drug development and deep-tech R&D are long-horizon, capital-intensive endeavors. Companies plan facilities, hiring, and research roadmaps around predictable incentive structures. When those structures change, capital migrates to states with more generous or more stable programs.

The opposition isn't limited to biotech. Fifty state assemblymembers (33 Democrats and 17 Republicans) signed a letter urging legislative leaders to reject the cap, noting that semiconductors, software, clean technology, aerospace, advanced manufacturing, and AI all depend on R&D credits. As they put it, capping innovation incentives "may generate short-term budgetary gains, but risks long-term economic consequences."

How does California's R&D tax credit work today?

California offers one of the most valuable state-level R&D programs in the U.S.:

The regular credit equals 15% of qualified research expenses (QREs) above a calculated base amount, with an additional 24% credit available for basic research payments to qualifying institutions. Research must be performed in California, and qualification follows the same four-part test used for the federal credit under IRC Section 41. The credit is nonrefundable, but unused amounts carry forward indefinitely, which is exactly why a usage cap matters so much for companies that have accumulated large credit balances.

Recent legislation (SB 711) also introduced an Alternative Simplified Credit (ASC) at 3% of QREs over a base amount for tax years beginning in 2025, giving startups and companies without deep gross-receipts history a simpler path to claiming.

Critically, California's credit stacks on top of the federal R&D tax credit, which has its own momentum right now: the One Big Beautiful Bill Act restored immediate expensing of domestic R&D costs under Section 174A, and eligible small businesses still have a window to claim retroactive benefits for 2022–2024 tax years.

What should R&D-intensive businesses do now?

The proposed cap is a reminder that innovation funding strategy can't be a year-end afterthought. Three takeaways for CFOs and CTOs:

  1. Claim whatyou'veearned every year, in every jurisdiction. With usage caps in play, credits stockpiled for "later" carry more risk than credits claimed and applied strategically. A coordinated federal-plus-state approach matters more than ever.
  2. Don't let headlines scare you off.The proposed cap targets California's largest corporate taxpayers.For the vast majority of growth-stage and mid-market innovators, the state's 15% credit remains fully accessible, and underutilized.
  3. Treat documentation as an asset.As states scrutinize whether creditsactually incentivize new research, well-documented claims that clearly map R&D activities to qualified expenses will stand up best; in California, with the IRS, and everywhere in between.

Maximize your federal and state R&D credits with Boast

Navigating shifting rules across federal and state programs is exactly why Boast exists. Since 2011, Boast has helped more than 2,000 companies across North America secure over $900 million in R&D tax credits, combining AI-powered software with in-house tax and technical experts to capture every eligible dollar, backed by a 100% audit defense commitment.

Whether you're building in California, claiming the federal credit under Section 41, or layering incentives across multiple states, Boast helps you turn challenging product development into non-dilutive funding.

Book a call with an R&D tax credit expert today.

Frequently Asked Questions: California's Proposed R&D Tax Credit Cap

California Governor Newsom’s 2026 budget proposal would permanently cap the state business tax credits companies can apply against their California tax bill to $5 million or 50% of tax liability; whichever is greater. If enacted, the cap would take effect for tax year 2027. This follows a temporary version of the same restriction already in place for 2024–2026.

No. The credit itself (a 15% rate on qualified research expenses above a calculated base amount) would remain intact. What changes is how quickly companies can use it. Unused credits still carry forward indefinitely, but the cap limits annual redemption, which is particularly significant for growth-stage companies that have accumulated large credit balances over time.

According to California’s Legislative Analyst’s Office, the cap would directly affect fewer than 100 of the state’s largest corporate taxpayers. For the vast majority of growth-stage and mid-market innovators, the current 15% credit remains fully accessible. That said, the proposal signals that state innovation incentives can change, making a proactive, well-documented claims strategy more important than ever.

Yes, and the combined benefit is substantial. California’s credit stacks on top of the federal R&D tax credit under IRC Section 41, which can offset up to 20% of qualified research expenses. Recent federal changes, including restored immediate expensing of domestic R&D costs under Section 174A, further strengthen the case for claiming both credits together through a coordinated strategy.

Boast combines AI-powered technology with in-house R&D tax specialists to help innovative businesses identify every qualifying activity, build audit-ready documentation, and optimize claims across federal and state programs simultaneously. Since 2011, Boast has helped more than 2,000 companies across North America secure over $900 million in R&D tax credits with approximately 5 hours of your team’s time required.